Skip to main content

Role for the left atrial appendage occlusion device in managing thromboembolic risk in atrial fibrillation

Buy Article:

$48.00 plus tax (Refund Policy)

Abstract:

Abstract

Only 50% of patients who would benefit from warfarin therapy for atrial fibrillation (AF) receive treatment because of clinical concerns regarding chronic anti‐coagulation. Percutaneous strategies to treat AF, including pulmonary vein isolation with a curative intent or atrioventricular nodal ablation and implantation of a permanent pacemaker for palliative rate control, have not eliminated the need to manage thromboembolic risk. With the development of a percutaneous left atrial appendage (LAA) occlusion device (the WATCHMAN percutaneous left atrial appendage occluder – Atritech Inc., Plymouth, MN, USA) for thromboembolic protection in non‐valvular AF a significant therapeutic option for select patients may be available. We present the first case performed in Australia (24 November 2009) and explore this new methodology.

Document Type: Research Article

DOI: http://dx.doi.org/10.1111/j.1445-5994.2011.02698.x

Affiliations: Monash Cardiovascular Research Centre, Monash Heart and Monash University Department of Medicine, Southern Health Network, Melbourne, Victoria, Australia

Publication date: March 1, 2012

bsc/imj/2012/00000042/00000003/art00005
dcterms_title,dcterms_description,pub_keyword
6
5
20
40
5

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more